Table 3.
Baseline |
2–4 weeks after RT |
||||||||
---|---|---|---|---|---|---|---|---|---|
Mean score (SD) |
p-valuea | Mean score (SD) |
p-valuea | Clinically important deterioration |
|||||
5-fraction schedule | 15-fraction schedule | 5-fraction schedule | 15-fraction schedule | 5-fraction schedule | 15-fraction schedule | p-valueb | |||
N | 105 | 94 | 105 | 94 | 105 | 94 | |||
EORT QLQ-C30/BR23 | |||||||||
Global health status (QL)c | 71.9 (17.2) | 72.9 (19.2) | p = 0.8 | 73.9 (14.8) | 67.4 (20.5) | p = 0.01 | 16 (15%) | 30 (32%) | p = 0.005 |
Functional scalesc | |||||||||
Physical functioning (PF2) | 85.1 (16.4) | 89.4 (11.6) | p = 0.1 | 87.0 (15.2) | 86.8 (13.6) | p = 0.6 | 7 (7%) | 23 (24%) | p = 0.0005e |
Social functioning (SF) | 85.1 (21.5) | 84.4 (22.5) | p = 0.9 | 87.6 (20.4) | 83.0 (21.9) | p = 0.03 | 12 (11%) | 29 (31%) | p = 0.0007e |
Future perspective (BRFU) | 60.6 (26.9) | 63.1 (26.1) | p = 0.5 | 66.3 (22.9) | 59.9 (24.7) | p = 0.06 | 13 (12%) | 20 (21%) | p = 0.09 |
Symptom scalesd | |||||||||
Fatigue (FA) | 27.5 (19.6) | 26.7 (22.6) | p = 0.5 | 28.7 (22.2) | 35.2 (23.4) | p = 0.07 | 31 (30%) | 47 (50%) | p = 0.003e |
Pain (PA) | 18.7 (21.3) | 15.4 (17.7) | p = 0.3 | 16.2 (18.1) | 20.2 (21.7) | p = 0.2 | 23 (22%) | 35 (37%) | p = 0.02 |
Arm symptoms (BRAS) | 10.4 (13.7) | 10.4 (15.4) | p = 0.7 | 9.6 (13.2) | 9.1 (14.0) | p = 0.6 | 18 (17%) | 21 (22%) | p = 0.4 |
Breast symptoms (BRBS) | 16.7 (15.6) | 15.8 (16.6) | p = 0.5 | 23.7 (17.6) | 32.8 (19.9) | p = 0.001e | 31 (30%) | 56 (60%) | p = 0.0002e |
BREAST-Q | |||||||||
Satisfaction with breast c | 74.1 (16.8) | 71.6 (17.7) | p = 0.5 | 72.9 (17.5) | 67.4 (17.5) | p = 0.04 | 19 (18%) | 30 (32%) | p = 0.02 |
Physical well-being d | 14.2 (16.5) | 12.6 (14.1) | p = 0.5 | 18.4 (18.8) | 27.4 (20.3) | p = 0.001e | 28 (27%) | 45 (48%) | p = 0.002e |
Mann Whitney U test.
Chi squared test, For botha andb Bonferroni correction is applied (significance level: p < 0,005).
Higher score indicates better functioning.
Higher score indicates more symptoms.
Significance.